Hyloris Pharmaceuticals SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hyloris Pharmaceuticals SA - overview
Established
2012
Location
Liege, Walloon Region, Belgium
Primary Industry
Biotechnology
About
Based in Walloon Region, Belgium, and co-founded by Stijn Van Rompay (CEO) and Thomas Jacobsenin (Chief Business Development Officer) in 2012, Hyloris Pharmaceuticals SA operates as a biopharma company focused on transforming existing medications. The company is trading under Euronext Brussels Stock Exchange under the ticker symbol HYL. In March 2022, the firm raised PIPE funding. The company works on adding value to existing drug assets to provide better clinical outcomes and care for unmet medical needs.
Hyloris' product portfolio consists of specialty pharmaceuticals in several therapeutic areas, such as cardiovascular, oncology, and central nervous system disorders. The company as of April 2023, has 14 products in its pipeline with 2 marketed products and 3 high-barrier generics. Hyloris’ flagship commercial products include Maxigesic® IV, which is a non-opioid pain reliever, and Sotalol IV, which is used to treat atrial fibrillation. Other cardiovascular portfolios of the company include Aspirin IV, Milrinone, HY-074, etc and the value-added portfolio includes Tranexamic Acid, Miconazole – DB, Plecoid Agent, etc.
Current Investors
Saffelberg Investments, Noshaq, Scorpiaux
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Cardiology, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.hyloris.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Hyloris Pharmaceuticals SA - timeline of key events
Hyloris Pharmaceuticals SA - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | 175,000 | 2,780,255 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | 1488.7% | - | - | - |
| EBITDA (USD) | (281,342) | (460,280) | (485,371) | (6,924,000) | (7,613,610) | - | - | - |
| Operating Income (USD) | (281,342) | (460,280) | (485,371) | (7,025,000) | (7,613,610) | - | - | - |
| Operating Margin | - | - | - | (4014.3%) | (273.8%) | - | - | - |
| % EBITDA Margin | - | - | - | (3956.6%) | (273.8%) | - | - | - |
| NET Income (USD) | (275,449) | (457,792) | (435,501) | (7,145,000) | (7,684,897) | - | - | - |
| % Net Margin | - | - | - | (4082.9%) | (276.4%) | - | - | - |
Hyloris Pharmaceuticals SA - employee data
Hyloris Pharmaceuticals SA - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman Of The Board | BM | ||||||
| Chairman of the Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.